# Oxaliplatin

## Folep inj 100mg/20mL

| TAH Drug Code      | [IOXA1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOXA1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for (1) Adjuvant therapy following complete resection of the primary tumor in stage III colon cancer (Duke's C); (2) Treatment of metastatic colorectal cancer. The combination of oxaliplatin and fluoropyrimidine class drugs can be used for locally advanced， recurrent， or metastatic gastric cancer. The combination with 5-fluorouracil， leucovorin， and irinotecan (FOLFIRINOX) as a first-line treatment for metastatic pancreatic cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Adjuvant therapy post-surgery: 85 mg/m2 IVD every 2 weeks for a total of 12 cycles (6 months). Metastatic colorectal cancer: 85 mg/m2 IVD every 2 weeks. Locally advanced and recurrent/metastatic gastric cancer: 130 mg/m2 (given as 65 mg/m2 on days 1 and 8 of each 3-week cycle or 130 mg/m2 on day 1 only) IVD every 3 weeks. FOLFIRINOX: oxaliplatin (85mg/m2) IVD over 2 hours， followed by leucovorin (400mg/m2) IVD over 2 hours. Begin irinotecan (180mg/m2) 90 minutes into the leucovorin infusion via a Y-line. Immediately follow with an IV bolus of fluorouracil (400mg/m2). Then administer a 46-hour continuous infusion of fluorouracil (2400mg/m2). Repeat every 2 weeks for 6 months. Oxaliplatin is generally diluted in 250-500mL of 5% dextrose injection (50mg/mL) to a concentration between 0.2 to 0.70 mg/mL. The infusion is administered over 2-6 hours. For an oxaliplatin dose of 85 mg/m2， the maximum concentration for dilution is 0.70 mg/mL. Combination with fluoropyrimidines， oxaliplatin should be administered prior to fluoropyrimidine administration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Patients with known hypersensitivity to oxaliplatin. Breastfeeding. Patients with pre-existing bone marrow suppression (myelosuppression) prior to initiation of therapy (neutrophil counts < 2 x10^9/L or platelet counts < 100 x 10^9/L). Patients with pre-existing peripheral sensory neuropathies with functional impairment prior to initiation of therapy. Patients with severe renal impairment (creatinine clearance <30ml/min).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Abdominal pain (Monotherapy， 31%; combination therapy， up to 39%)， Constipation (Combination therapy， up to 32%)， Diarrhea (Monotherapy， 46%; combination therapy， up to 76%)， Loss of appetite (Monotherapy， 20%; combination therapy， up to 35%)， Nausea (Monotherapy， 64%; combination therapy， 64-83%)， Stomatitis (Monotherapy， 14%; combination therapy， up to 42%)， Vomiting (Monotherapy， 37%; combination therapy， 40-64%)， Anemia， All grades (Monotherapy， 64%; combination therapy， 25-81%)， Granulocytopenic disorder， Grade 3 and 4 (39-45%)， Leukopenia， All grades (Monotherapy， 13%; combination therapy， up to 85%)， Neutropenia， All grades (Monotherapy， 7%; combination therapy， 71-81%)， Thrombocytopenia， All grades (Monotherapy， 30%; combination therapy， 44-77%)， Abnormal alkaline phosphatase (Combination therapy， 14-16%)， ALT/SGPT level abnormal (Monotherapy， 36%; combination therapy， 5-31%)， Serum aspartate aminotransferase level outside reference range (Monotherapy， 54%; combination therapy， 11-47%)， Backache (Monotherapy， 11%; combination therapy， 19%)， Paresthesia (62-77%)， Cough (Monotherapy， 11%; combination therapy， up to 35%)， Fatigue (Monotherapy， 61%; combination therapy， up to 70%)， Fever (Monotherapy， 25%; combination therapy， 29%). Serious: Edema (Monotherapy， 5%; combination therapy， up to 15%)， Prolonged QT interval， Torsades de pointes， Metabolic acidosis， Bowel obstruction， Colitis， Including clostridium difficile diarrhea， Pancreatitis， acute， Anemia， Grade 3 or 4 (Monotherapy， 1%; combination therapy， 1-3%)， Febrile neutropenia (Combination therapy， up to 12%)， Hemolytic anemia， Immuno-allergic， Leukopenia， Grade 3 or 4 (Combination therapy， 13-24%)， Neutropenia， Grade 3 or 4 (Combination therapy， 36-53%)， Thrombocytopenia， Grade 3 or 4 (Monotherapy， 3%; combination therapy， 2-5%)， Thrombocytopenia， Immuno-allergic， Increased liver function test (Combination therapy， 57%)， Veno-occlusive disease of the liver， Anaphylaxis， Hypersensitivity reaction (Monotherapy， grade 3 or 4， 1-3% ; combination therapy， all grades， 6-12%)， Infusion reaction， Rhabdomyolysis， Dysesthesia， Pharyngolaryngeal (1-38%)， Neuropathy， Acute or persistent (Overall neuropathy， 69-92%; acute neuropathy， 56%; persistent neuropathy， 21-60%)， Posterior reversible encephalopathy syndrome (<0.1%)， Transient visual loss， Hearing loss， Hemolytic uremic syndrome， Tubulointerstitial nephritis， acute， Dyspnea (Monotherapy， 13%; combination therapy， up to 20%)， Pneumonitis (Severe)， Pulmonary fibrosis (<1%)， Angioedema， Sepsis. |
| Pregnancy          | Contraindicated – 1st Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/oxaliplatin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

